biosimulytics

Uniting Minds Across Borders: Celebrating Our Partnership with Viridien and Binarii Labs 🌍🤝 We recently had the pleasure of hosting our esteemed partners from Viridien (all the way from France) at our office in NovaUCD. It was a fantastic opportunity to discuss our ongoing partnership and chart out our future plans together. 🤝 At biosimulytics, maintaining a high-performing #HPC and #AI environment to optimize our CHEMINIA platform is essential and Viridien’s customized solutions have been instrumental to our developments. We also had the privilege of engaging in insightful discussions with our ongoing partners at Binarii Labs , a leading cybersecurity start-up based in Ireland. Together, we explored innovative solutions to enhance the security of our platform, ensuring we continue to deliver top-notch, secure services to our clients. 🔒✨ A big thank you to everyone involved for their dedication and collaborative spirit. Here’s to many more innitiatives and groundbreaking innovations! #Biosimulytics #Viridien #Partnerships #Innovation #CyberSecurity #FuturePlans #HealthTech #Biotech #EITDigital #EICaccelerator 

Recently featured in Science Computing World's white paper, our AI-driven predictive simulation works with Viridien HPC, AI and Cloud to transform pharmaceutical R&D. Here’s how we’re making an impactful : ✅ Faster results: Our simulations dramatically accelerate trial timelines, driving pharmaceutical innovation forward.   ✅ Cost savings: We empower early-stage drug discovery by significantly reducing costs through precise in-silico experiments.   ✅ Market leadership: We stand strong in an industry poised to exceed $10 billion by 2030, shaping the future of healthcare.  📘 Curious how we’re shaping the future of drug discovery? Explore our feature in Science Computing World's latest white paper: https://lnkd.in/ebkd5KVt #Innovation #AI #PharmaTech #DrugDiscovery

Today, we proudly celebrate the 5th anniversary of biosimulytics🎉 As a spinout from UCD School of Chemical & Bioprocess Engineering we've come a long way in just five years, making significant strides in building the company and developing our advanced simulation technology. Some Proud Moments and Achievements So Far: 🏆 2019 Start-Up of the Year: In our first year, we were honored to win University College Dublin's Start-Up of the Year Award. This recognition was a huge boost for our young company, validating our vision and efforts. 🌟 2024 EIT Awards Finalist: Fast forward to this year, and we were thrilled to be named a finalist in the prestigious EIT - European Institute of Innovation and Technology Awards. This accolade highlights the significant impact we've made to date. 👥 Team Growth: It all started with just our cofounders Peter, Christian, and Niall, who had the research and passion to make a difference. Today, our team has grown to 9 talented individuals, each bringing unique skills and energy to our mission. 🤝 Strategic Partnerships: Our collaborations with firms like Binarii Labs and Viridien HPC, AI and Cloud have been instrumental in enhancing our capabilities and accelerating our progress. These partnerships help us use the latest technology to help develop better medicines faster. 🚀 EIC Accelerator Success: We joined the EIC Accelerator and successfully completed our 1-year review this year. This was a massive milestone, validating our progress, hard work, and dedication. We've faced challenges, celebrated victories, and continuously pushed ourselves to innovate and excel. As we look to the future, we remain committed to our mission of transforming the pharmaceutical industry. We're excited about the road ahead and the many breakthroughs yet to come. Thank you to everyone who has been part of our story. We couldn't have done it without you! 🚀 Cheers to the next chapter! 🚀 #StartUp #Pharmaceuticals #Biosimulytics #Milestone #Teamwork #AI #Quantum #Celebrate Viridien HPC, AI and Cloud NovaUCD Binarii Labs

At biosimulytics, we are thrilled to leverage the expertise of Viridien (formarly CGG) in HPC Cloud and software optimization. This partnership has accelerated our crystal structure simulations to give innovators the best posible insights, more efficiently. Thanks to this partnership, we are confidently on track to achieve our goals in terms of speed, cost, utility, and usability. Learn more about our exciting collaboration here: https://lnkd.in/esR26dKv #healthtech #AI #HPC #deeptech #Pharma #biosimulytics #Partnership Viridien HPC, AI and Cloud

What's the cost of not understanding all the different ways your drug can crystalize? What's the cost of MISSING SOMETHING? Apart from potentially harming patients, a single change in a drug’s crystal form can lead to market withdrawal and millions in losses. ⚠️The case of Ritonavir is one of many to show this⚠️ Ritonavir, an antiretroviral drug approved in 1996, was an innovative new HIV treatment. It was initially thought to exist in one crystalline form (Form I) which proved to be quite effective. In 1998, however, researchers discovered a new, more stable polymorph (Form II). Form II was less soluble, leading to reduced bioavailability and effectiveness in patients. Luckily, in this case, there was no direct evidence that patients were harmed in terms of severe adverse effects from the drug itself. However, there were serious concerns about the drug’s reduced effectiveness due to formulation issues. As a result, Abbott Laboratories had to withdraw ritonavir from the market, incurring an estimated loss of ⚠️$250 million⚠️. Key Lessons Learned: 💡Importance of Polymorph Screening: This case highlights the necessity of thorough polymorph screening to avoid similar issues in future drug development. 💡Understanding Stability: There’s a critical need for deeper insights into the stability and solubility of different polymorphs early on in tyhe process. 💡Ongoing Research: Even years later, new polymorphs of ritonavir continue to be discovered, demonstrating the complexity of polymorphism and need for advanced technologies in this space. Luckily, Crystal Structure Prediction (CSP) presents exciting opportunities in drug development, including: ✅Accelerated Drug Discovery: Predicting stable polymorphs early can speed up the discovery phase. ✅Improved Formulation Strategies: CSP helps design formulations that optimize solubility and bioavailability. ✅Enhanced Safety and Efficacy: Selecting the most suitable polymorph can improve the drug’s safety profile. ✅Cost Efficiency: Reducing the need for extensive experimental screening saves time and resources. ✅Regulatory Compliance: CSP provides systematic data necessary for meeting regulatory requirements. ✅Facilitating Novel Drug Design: CSP aids in designing new drugs by predicting how structural modifications affect crystallization. By prioritizing polymorph screening and leveraging the opportunities offered by CSP, we can enhance drug safety and efficacy. Our advanced crystal structure prediction technologies can enable drug developers to see the full polymorph panoply - including potential forms that traditional experiment-based screenings would miss. #Innovation #HealthTech #Biosimulytics #Quantum #HPC #EICAccelerator #EITDigital NovaUCD Viridien HPC, AI and Cloud

In the world of pharmaceuticals, polymorphism can be a blessing and a curse. While it opens doors to innovative formulations, it also presents significant risks that can impact patient safety and drug efficacy. 🤔So, what exactly is Polymorphism? Simply put, polymorphism is the ability of a substance to exist in different crystalline forms. A molecule can arrange itself into various crystal lattices, each with distinct physical and chemical properties. For example, one polymorph might dissolve quickly, while another dissolves slowly, affecting absorption. This variability can lead to patients receiving either too little or too much of the active ingredient, which can be dangerous! ⚠️ Apart from mitigating risks, understanding the full polymorph landscape offers many exciting opportunities in drug development! To name a few: ⚛️The effectiveness of a drug can depend on its polymorphic form. If a certain form is more soluble, it may be absorbed better by the body, leading to improved efficacy. Identifying that form early on can help develop the best possible treatment as soon as possible. ⚛️ Identifying and selecting stable polymorphs can ensure the long-term effectiveness and reliability of the drug. ⚛️Understanding polymorphic properties allows for the creation of more effective delivery systems. By optimizing solubility, stability, release profiles, and targeting capabilities, pharmaceutical developers can significantly enhance treatment outcomes. ⚛️ Different polymorphs can affect how a drug is manufactured. Some forms might be easier to produce or process than others. Identifying optimal forms can significantly enhance operational efficiencies down the line! Understanding the different polymorphs of a molecule? Easier said than done! Crystallization can be quite the puzzle, with several factors influencing how molecules stack up. And as active pharmaceutical ingredients (APIs) get bigger and more complex, the number of potential forms skyrockets, making it harder and harder to identify all the variants, especially when relying on traditional experimental screenings. That's where 🎆Crystal Structure Prediction (CSP)🎆 comes in. Advanced CSP technologies allow researchers predict possible crystal forms before they even start synthesizing, which speeds up the process of exploring polymorphs. By applying advanced computational methods, CSP solutions help identify stable forms, guiding researchers to the most promising candidates for further study, saving both time and resources. Leveraging these innovative techniques can improve drug safety, efficacy, and ultimately, patient outcomes. If you’re interested in discussing how advanced CSP can benefit your projects, feel free to reach out! 📩 #Pharmaceuticals #Polymorphism #CSP #Innovation #DrugDevelopment #PatientSafety #DeepTech #Startup #EITDigital #EICaccelerator  Viridien NovaUCD

In the world of pharmaceuticals, polymorphism can be a blessing and a curse. While it opens doors to innovative formulations, it also presents significant risks that can impact patient safety and drug efficacy. 🤔So, what exactly is Polymorphism? Simply put, polymorphism is the ability of a substance to exist in different crystalline forms. A molecule can arrange itself into various crystal lattices, each with distinct physical and chemical properties. For example, one polymorph might dissolve quickly, while another dissolves slowly, affecting absorption. This variability can lead to patients receiving either too little or too much of the active ingredient, which can be dangerous! ⚠️ Apart from mitigating risks, understanding the full polymorph landscape offers many exciting opportunities in drug development! To name a few: ⚛️The effectiveness of a drug can depend on its polymorphic form. If a certain form is more soluble, it may be absorbed better by the body, leading to improved efficacy. Identifying that form early on can help develop the best possible treatment as soon as possible. ⚛️ Identifying and selecting stable polymorphs can ensure the long-term effectiveness and reliability of the drug. ⚛️Understanding polymorphic properties allows for the creation of more effective delivery systems. By optimizing solubility, stability, release profiles, and targeting capabilities, pharmaceutical developers can significantly enhance treatment outcomes. ⚛️ Different polymorphs can affect how a drug is manufactured. Some forms might be easier to produce or process than others. Identifying optimal forms can significantly enhance operational efficiencies down the line! Understanding the different polymorphs of a molecule? Easier said than done! Crystallization can be quite the puzzle, with several factors influencing how molecules stack up. And as active pharmaceutical ingredients (APIs) get bigger and more complex, the number of potential forms skyrockets, making it harder and harder to identify all the variants, especially when relying on traditional experimental screenings. That's where 🎆Crystal Structure Prediction (CSP)🎆 comes in. Advanced CSP technologies allow researchers predict possible crystal forms before they even start synthesizing, which speeds up the process of exploring polymorphs. By applying advanced computational methods, CSP solutions help identify stable forms, guiding researchers to the most promising candidates for further study, saving both time and resources. Leveraging these innovative techniques can improve drug safety, efficacy, and ultimately, patient outcomes. If you’re interested in discussing how advanced CSP can benefit your projects, feel free to reach out! 📩 #Pharmaceuticals #Polymorphism #CSP #Innovation #DrugDevelopment #PatientSafety #DeepTech #Startup #EITDigital #EICaccelerator  Viridien NovaUCD

Enhancing Data Security with Binarii Labs At Binarii Labs, we specialise in delivering cutting-edge data security solutions tailored to diverse industries, including the pharmaceutical sector. See what our esteemed clients at biosimulytics have shared about their experiences. We are privileged to assist visionary companies like biosimulytics in reaching their data security objectives. Explore how our solutions can revolutionise your business as well. Reach out to our experts today at www.binariilabs.com.

👏Congratulations to Binarii Labs on this outstanding milestone! Well done to the entire team!👏

Our team is growing! 👋 Meet Lorella, our new Computational Chemist! 👋 Joining us all the way from Malta, Lorella brings a wealth of experience and a passion for harnessing computational power to drive innovation in drug development. With her expertise in analysing and predicting crystallographic behaviour, particularly in polymorphism and co-crystallization, Lorella is set to make a significant impact on our projects. 💡 What Excites Lorella About Joining Biosimulytics? “Being part of an innovative project that aims to accelerate drug development through accurate predictions, ultimately reducing the time required to bring new drugs to patients!” 🔬 Why did Lorella Chose Computational Chemistry? “I was inspired by the immense potential of computational power to facilitate development and innovation, providing an alternative way to investigate science and access a vast space of analysis and discovery.” 📈 Lorella’s Vision for the Future: “Computational chemistry is becoming essential for understanding scientific phenomena and guiding experimental work, leading to both financial and environmental benefits. This integration will continue to drive advancements in the pharmaceutical industry.” We are confident that Lorella’s expertise in crystallography and her passion for using statistical methods to extract information and make predictions will be invaluable to our mission. Welcome aboard, Lorella Spiteri! #TeamGrowth #Innovation #ComputationalChemistry #DrugDevelopment #DeepTech #StartUp #EIC #EITDigital Viridien NovaUCD